Exhibit 99.1 4DMT Reports First Quarter 2024 Financial Results and Operational Highlights EMERYVILLE, Calif., May. 9, 2024 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading clinical-stage genetic medicines company focused on unlocking the full potential of genetic medicines to treat large market diseases, today reported first quarter 2024 financial results and provided operational highlights. "The first quarter of 2024 kicks off another transformative year for 4DMT ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-39782 4D Molecular Therapeutics, Inc. (Exact name of registrant as specified in its Charter) Delaware 47-3506994 (State or other ...

Wall Street expects a year-over-year increase in earnings on higher revenues when 4D Molecular Therapeutics, Inc. (FDMT) reports results for the quarter ended March 2024. While this widely-known consensus outlook is important in gauging the company's earnings picture, a powerful factor that could impact its near-term stock price is how the actual results compare to these estimates.The stock might move higher if these key numbers top expectations in the upcoming earnings report. On the other hand, if they mi ...

Preclinical data for 4D-175 for geographic atrophy to be presented in an oral presentation4D-150 PRISM randomized Phase 2 Dose Expansion Cohort (N=51) 24-week encore results to be presented in a poster EMERYVILLE, Calif., May 01, 2024 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (NASDAQ:FDMT, 4DMT or the Company))), a leading clinical-stage genetic medicines company focused on unlocking the full potential of genetic medicines to treat large market diseases, today announced presentations at the 2024 Associa ...

EMERYVILLE, Calif., March 04, 2024 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading clinical-stage genetic medicines company focused on unlocking the full potential of genetic medicines to treat large market diseases, today announced that management will participate in fireside chats at upcoming investor conferences in March. Members of the management team will also be available for one-on-one meetings. Leerink Partners Global Biopharma Conference 2024 Presentatio ...

EMERYVILLE, Calif., March 04, 2024 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading clinical-stage genetic medicines company focused on unlocking the full potential of genetic medicines to treat large market diseases, today announced that management will participate in fireside chats at upcoming investor conferences in March. Members of the management team will also be available for one-on-one meetings. Leerink Partners Global Biopharma Conference 2024 Presentatio ...

4D Molecular Therapeutics, Inc. (FDMT) came out with a quarterly loss of $0.77 per share versus the Zacks Consensus Estimate of a loss of $0.68. This compares to loss of $0.84 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -13.24%. A quarter ago, it was expected that this company would post a loss of $0.67 per share when it actually produced a loss of $0.24, delivering a surprise of 64.18%.Over the last four quarters, the com ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-39782 4D Molecular Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 47-3506994 (State or other juri ...

财务状况 - 4DMT在2023年全年的财务报告显示，现金及现金等价物和可交易证券总额为299,186千美元，较2022年底的218,462千美元有所增加[12] - 4DMT的总资产在2023年底为339,891千美元，较2022年底的261,846千美元有所增加[12] 研发费用 - 4DMT的研发费用在2023年达到97,096千美元，较2022年的80,253千美元有所增加[6] 合作与许可 - 4DMT在2023年的合作和许可收入为20,723千美元，较2019年的3,129千美元有显著增长[11] - 4DMT与Astellas Pharma签订了许可协议，用于罕见单基因眼科疾病的治疗，获得了2,000万美元的前期付款和高达9,425万美元的潜在未来里程碑[4] - 4DMT与Arbor Biotechnologies达成战略合作伙伴关系，共同开发基于AAV递送的CRISPR/Cas的治疗药物，用于中枢神经系统治疗领域，拟定了最多六个产品候选药物[4] 净亏损 - 4DMT的净亏损在2023年为100,837千美元，较2022年的107,494千美元有所减少[11] - 4DMT的净亏损在2023年为100,837千美元，较2022年的107,494千美元有所减少[6]

EMERYVILLE, Calif., Feb. 06, 2024 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT), a leading clinical-stage genetic medicines company focused on unlocking the full potential of genetic medicines to treat large market diseases, announced today that it priced an upsized underwritten public offering of 6,586,015 shares of its common stock at a public offering price of $29.50 per share and, in lieu of shares of common stock, to certain investors, pre-funded warrants to purchase 3,583,476 share ...